Search Close Search
Search Close Search
Page Menu

Idanis Berrios Morales, MD, publications

Total: 8 results
  • A single-arm, open-label pilot study of neuroimaging, behavioral, and peripheral inflammatory correlates of mindfulness-based stress reduction in multiple sclerosis

    Tuesday, June 18, 2024
    Author(s): Christopher C Hemond,Mugdha Deshpande,Idanis Berrios-Morales,Shaokuan Zheng,Jerrold S Meyer,George M Slavich,Steven W Cole
    Source: Scientific reports
    Multiple sclerosis (MS) is a chronic neurological disease frequently associated with significant fatigue, anxiety, depression, and stress. These symptoms are difficult to treat, and prominently contribute to the decreases in quality of life observed with MS. The underlying mechanisms of these "silent" symptoms are not well understood and include not just the psychological responses to a chronic disease, but also biological contributions from bidirectional psycho-neuro-immune (dys)regulation of...
  • Chemotherapy-associated hemorrhagic posterior reversible encephalopathy syndrome (PRES) with considerations for circle of Willis variants on cerebral blood flow and autoregulation: A case report

    Friday, February 23, 2024
    Author(s): Bahadar S Srichawla,Kendall Presti,Vincent Kipkorir,Idanis Berrios Morales
    Source: Medicine
    RATIONALE: Hodgkin lymphoma, a lymphatic system cancer, is treated by chemotherapy, radiation therapy, and hematopoietic stem cell transplantation. Posterior reversible encephalopathy syndrome (PRES) is a rare neurotoxic effect associated with several drugs and systemic conditions. This case study emphasizes the potential risks of intensive chemotherapy regimens and postulates the impact of the circle of Willis variants on the heterogeneity of hemispheric lesions in PRES.
  • Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool

    Monday, November 06, 2023
    Author(s): Nananda F Col,Andrew J Solomon,Enrique Alvarez,Lori Pbert,Carolina Ionete,Idanis BerriosMorales,Jennifer Chester,Christen Kutz,Crystal Iwuchukwu,Terrie Livingston,Vicky Springmann,Hannah V Col,Long H Ngo
    Source: Multiple sclerosis and related disorders
    CONCLUSIONS: MS-SUPPORT was strongly endorsed by patients and is feasible to use in clinical settings. MS-SUPPORT increased the short-term probability of taking and adhering to a DMT, and improved long-term mental health. Study limitations include selection bias, response bias, social desirability bias, and recall bias. Exploring approaches to reinforcement and monitoring its implementation in real-world settings should provide further insights into the value and utility of this new SDM tool.
  • The impact of socioeconomic status on mental health and health-seeking behavior across race and ethnicity in a large multiple sclerosis cohort

    Saturday, December 25, 2021
    Author(s): Daniela A Pimentel Maldonado,Justin R Eusebio,Lilyana Amezcua,Eleni S Vasileiou,Ellen M Mowry,Christopher C Hemond,Raffaella Umeton Pizzolato,Idanis Berrios Morales,Irina Radu,Carolina Ionete,Kathryn C Fitzgerald
    Source: Multiple sclerosis and related disorders
    CONCLUSION: Higher SES was associated with a lower burden of psychiatric symptoms and with a higher likelihood of self-reported symptom recovery after receiving mental health treatment. Attitudes regarding mental health care delivery in MS varied according to racial and ethnic background. Future longitudinal studies in more diverse populations should assess whether co-location of mental health services with MS care helps to reduce the gap between access and need of mental health care in MS.
  • A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis

    Saturday, November 14, 2020
    Author(s): Jorge Acevedo Herman,Farnaz Khalighinejad,Katherine York,Irina Radu,Idanis Berrios Morales,Carolina Ionete,Christopher C Hemond
    Source: Multiple sclerosis and related disorders
    Multiple sclerosis (MS) is a chronic and progressive neurological disease characterized by recurrent episodes of inflammatory demyelination of the brain and spinal cord. Alemtuzumab has been previously shown in large phase III trials to be an effective therapy in reducing MS clinical flares as well as new radiological activity and atrophy rates. The purpose of this study was to examine real-world effectiveness and safety data from a large cohort of people treated with alemtuzumab at an academic...
  • A Novel Tool to Improve Shared Decision Making and Adherence in Multiple Sclerosis: Development and Preliminary Testing

    Friday, November 01, 2019
    Author(s): Nananda Col,Enrique Alvarez,Vicky Springmann,Carolina Ionete,Idanis Berrios Morales,Andrew Solomon,Christen Kutz,Carolyn Griffin,Brenda Tierman,Terrie Livingston,Michelle Patel,Danny van Leeuwen,Long Ngo,Lori Pbert
    Source: MDM policy & practice
    Background. Most people with multiple sclerosis (MS) want to be involved in medical decision making about disease-modifying therapies (DMTs), but new approaches are needed to overcome barriers to participation. Objectives. We sought to develop a shared decision-making (SDM) tool for MS DMTs, evaluate patient and provider responses to the tool, and address challenges encountered during development to guide a future trial. Methods. We created a patient-centered design process informed by image...
  • Whose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals

    Tuesday, August 15, 2017
    Author(s): Nananda F Col,Andrew J Solomon,Vicky Springmann,Calvin P Garbin,Carolina Ionete,Lori Pbert,Enrique Alvarez,Brenda Tierman,Ashli Hopson,Christen Kutz,Idanis Berrios Morales,Carolyn Griffin,Glenn Phillips,Long H Ngo
    Source: Medical decision making : an international journal of the Society for Medical Decision Making
    CONCLUSIONS: Differences between the treatment goals of patients and HCPs underscore the limitations of using HCP- or investigator-identified goals. This new adaptation of cognitive mapping is a patient-centered approach that can be used to generate and organize the outcomes and attributes for values clarification exercises while minimizing investigator bias and maximizing relevance to patients.
  • The varieties of psychosis in multiple sclerosis: A systematic review of cases

    Sunday, March 12, 2017
    Author(s): Carlos R Camara-Lemarroy,Beatriz E Ibarra-Yruegas,Rene Rodriguez-Gutierrez,Idanis Berrios-Morales,Carolina Ionete,Peter Riskind
    Source: Multiple sclerosis and related disorders
    CONCLUSIONS: MS can present with a variety of psychotic symptoms. The presence of enhancing lesions and steroid-responsiveness suggests these could be characterized as flares.